NEUROCRINE BIOSCIENCES INC Retained Earnings
NEUROCRINE BIOSCIENCES INC (NBIX) had Retained Earnings of $724.00 million as of 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-07-31
- 2026-06-30: Retained Earnings (Accumulated Deficit) $724.00M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) $589.60M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) $447.70M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) $294.00M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | $724.00M 10-Q · filed 2026-07-31 |
| 2026-03-31 | $589.60M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $447.70M 10-Q · filed 2026-07-31 |
| 2025-09-30 | $294.00M 10-Q · filed 2025-10-28 |
| 2025-06-30 | $84.50M 10-Q · filed 2025-07-30 |
| 2025-03-31 | -$5.30M 10-Q · filed 2025-05-05 |
| 2024-12-31 | $29.20M 10-K · filed 2026-02-11 |
| 2024-09-30 | $81.10M 10-Q · filed 2024-10-30 |
| 2024-06-30 | -$48.70M 10-Q · filed 2024-08-01 |
| 2024-03-31 | -$113.70M 10-Q · filed 2024-05-01 |
| 2023-12-31 | -$157.10M 10-K · filed 2025-02-10 |
| 2023-09-30 | -$304.80M 10-Q · filed 2023-10-31 |
| 2023-06-30 | -$387.90M 10-Q · filed 2023-08-01 |
| 2023-03-31 | -$483.40M 10-Q · filed 2023-05-03 |
| 2022-12-31 | -$406.80M 10-K · filed 2024-02-09 |
| 2022-09-30 | -$495.80M 10-Q · filed 2022-11-01 |
| 2022-06-30 | -$564.30M 10-Q · filed 2022-08-04 |
| 2022-03-31 | -$547.40M 10-Q · filed 2022-05-04 |
| 2021-12-31 | -$635.80M 10-K · filed 2023-02-09 |
| 2021-09-30 | -$628.50M 10-Q · filed 2021-11-01 |
| 2021-06-30 | -$651.00M 10-Q · filed 2021-08-03 |
| 2021-03-31 | -$693.30M 10-Q · filed 2021-05-05 |
| 2020-12-31 | -$725.40M 10-K · filed 2022-02-11 |
| 2020-09-30 | -$1.07B 10-Q · filed 2020-11-09 |
| 2020-06-30 | -$1.02B 10-Q · filed 2020-08-03 |
| 2020-03-31 | -$1.10B 10-Q · filed 2020-05-06 |
| 2019-12-31 | -$1.13B 10-K · filed 2021-02-05 |
| 2019-09-30 | -$1.17B 10-Q · filed 2019-11-04 |
| 2019-06-30 | -$1.22B 10-Q · filed 2019-07-29 |
| 2019-03-31 | -$1.27B 10-Q · filed 2019-04-29 |
| 2018-12-31 | -$1.18B 10-K · filed 2020-02-07 |
| 2018-09-30 | -$1.20B 10-Q · filed 2018-11-05 |
| 2018-06-30 | -$1.25B 10-Q · filed 2018-07-31 |
| 2018-03-31 | -$1.24B 10-Q · filed 2018-04-30 |
| 2017-12-31 | -$1.20B 10-K · filed 2019-02-08 |
| 2017-09-30 | -$1.21B 10-Q · filed 2017-11-01 |
| 2017-06-30 | -$1.19B 10-Q · filed 2017-08-03 |
| 2017-03-31 | -$1.13B 10-Q · filed 2017-05-09 |
| 2016-12-31 | -$1.06B 10-K · filed 2018-02-13 |
| 2016-09-30 | -$1.01B 10-Q · filed 2016-11-02 |
| 2016-06-30 | -$974.78M 10-Q · filed 2016-08-03 |
| 2016-03-31 | -$934.50M 10-Q · filed 2016-05-05 |
| 2015-12-31 | -$915.23M 10-K · filed 2017-02-14 |
| 2015-09-30 | -$885.92M 10-Q · filed 2015-10-29 |
| 2015-06-30 | -$851.48M 10-Q · filed 2015-07-29 |
| 2015-03-31 | -$827.50M 10-Q · filed 2015-04-30 |
| 2014-12-31 | -$826.30M 10-K · filed 2016-02-11 |
| 2014-09-30 | -$806.86M 10-Q · filed 2014-11-04 |
| 2014-06-30 | -$790.99M 10-Q · filed 2014-08-06 |
| 2014-03-31 | -$777.61M 10-Q · filed 2014-05-01 |
| 2013-12-31 | -$765.76M 10-K · filed 2015-02-09 |
| 2013-09-30 | -$755.12M 10-Q · filed 2013-10-29 |
| 2013-06-30 | -$743.99M 10-Q · filed 2013-07-26 |
| 2013-03-31 | -$731.75M 10-Q · filed 2013-05-02 |
| 2012-12-31 | -$719.67M 10-K · filed 2014-02-11 |
| 2012-09-30 | -$729.16M 10-Q · filed 2012-10-31 |
| 2012-06-30 | -$726.09M 10-Q · filed 2012-07-31 |
| 2012-03-31 | -$725.58M 10-Q · filed 2012-05-02 |
| 2011-12-31 | -$724.70M 10-K · filed 2013-02-08 |
| 2011-09-30 | -$726.03M 10-Q · filed 2011-10-31 |
| 2011-06-30 | -$757.41M 10-Q · filed 2011-07-29 |
| 2010-12-31 | -$762.27M 10-K · filed 2012-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |